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Introduction process may offer novel avenues for therapeutic inter-
vention.
Apoptosis, or programmed cell death, was first de-
scribed by Kerr et al.1 in 1972 as a specific type of cell
death morphologically distinct from necrosis. Apo-
Molecular Aspects of Apoptosisptotic cells undergo shrinkage with nuclear con-
densation and the formation of membrane-bound
Since the original morphological description of apo-vesicles called apoptotic bodies. These are phago-
ptosis many molecular mechanisms that characterisecytosed by adjacent cells and macrophages without
the apoptotic pathway have been identified. Apoptosisinducing an inflammatory response. In contrast, nec-
is controlled by a well-ordered cascade of cellularrotic cells sustain membrane damage leading to the
events that may be divided into four stages (initiation,release of pro-inflammatory intracellular contents.
control/execution, structural/morphological al-Apoptosis although recognised to be fundamentally
teration and phagocytic recognition) (Fig. 1). Initiationimportant in development also occurs in normal
of apoptosis may occur following the binding of deathphysiological circumstances. Apoptotic vascular
promoting factors (e.g. Tumour Necrosis Factor (TNF)smooth muscle cells (VSMCs) have been identified
and Fas Ligand) to cell surface TNF and Fas deathduring the physiological regression and closure of
receptors or by a withdrawal of survival factors (e.g.the human ductus arteriosus before birth.2 Similarly,
reduced insulin-like growth factor, loss of cell–cellapoptotic VSMCs and endothelial cells are present in
and cell–matrix contact) acting via the mitochondria.umbilical veins and arteries following the significant
Alternatively apoptosis may be initiated by ionisinghaemodynamic changes that occur during birth.3 Such
radiation or chemotherapeutic agents acting directlyapoptosis appears to be triggered by a reduction in
on DNA.blood flow. Further support comes from experimental
The control and execution stage of apoptosis isstudies using immature rabbits which demonstrate
dependent on the sequential activation of a group ofthat reducing flow in the common carotid artery, by
cysteine proteases referred to as caspases. Activationligating the external carotid, results in both VSMC and
of caspase-8 occurs following binding of the cell surfaceendothelial cell apoptosis.4 The normal blood vessel
death-receptors (TNF and Fas).6 Caspase-9 is activatedwall is characterised by a low endothelial cell turnover
by cytochrome C released from mitochondria stim-with a variety of mechanisms affording protection
ulated by the withdrawal of survival factors. Bothagainst apoptosis.5 Indeed, recent data indicate that
caspase-8 and 9 can activate the final executioner,apoptosis may be important in the pathophysiology
caspase-3, which in turn causes the irreversible frag-of vascular disease. A better understanding of this
mentation and degradation of DNA.
Control of the execution phase is achieved by anti-
∗ Please address all correspondence to: T. C. F. Sykes, Department apoptotic proteins belonging to the Bcl-2 family (Bcl-of Vascular Surgery, Research Institute, Lincoln House, Birmingham
Heartlands Hospital, Birmingham B9 5SS, U.K. 2, Bcl-XL) inhibiting pro-apoptotic proteins (Bax and
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Fig. 2. A schematic summary of pro-apoptotic and survival factors
typically affecting the endothelial cell. A loss of survival factors will
also precipitate apoptosis. ROS (reactive oxygen species), VEGF
(Vascular endothelial cell growth factor).
apoptosis in tissue sections. The major drawback of
the TUNEL technique is that nuclei can be stainedFig 1. A schematic diagram illustrating four functional stages of
apoptosis and the three major pathways through which the cascade non-specifically due to differences in cell fixation and
of cellular events can proceed. The three pivotal caspases (8, 9 also non-nuclear structures in atherosclerotic plaquesand 3) are shown with caspase-3, the final executioner, causing
may be stained. It is recommended that this techniqueirreversible DNA damage and loss of cell viability. Control is
achieved with the regulatory pro and anti-apoptotic proteins (Bax/ be used in conjunction with an additional mor-
Bid & Bcl2 respectively). TNF (Tumour necrosis factor/receptor), phological method.5Fas L (Fas Ligand), Fas (Fas receptor), DD (TNF death domain
Additional methods, suitable for in vitro use only,protein), FADD (Fas-associated death domain), IGF (Insulin-like
growth factor) and PS (Phosphatidylserine). include the detection of externalised phos-
phatidylserine (PS) residues, that occurs in early apo-
ptosis, with a fluorescein (FITC) conjugate of Annexin-Bid) that facilitate the release of cytochrome C from the
V, a protein that has a high natural affinity for PS.mitochondria. The relative amounts of these proteins
This method allows quantitative assessment of apo-determines whether the cell undergoes apoptosis or
ptotic cells either by fluorescence microscopy or flownot. Structural and morphological changes to the cell
cytometry.occur following the internucleosomal fragmentation
of DNA leading to an irreversible loss of cell viability.
Early apoptotic cells are characterised by ex-
ternalisation of phosphatidylserine (PS) residues, Pro-apoptotic Factors Implicated in Vascular Cell
which are normally situated on the inner leaflet of the Apoptosis
plasma membrane. This feature facilitates the specific
recognition of apoptotic cells by macrophages enabling In vitro studies have shown that extracellular agents,
their elimination by phagocytosis. including well characterised cardiovascular risk fac-
The efficient removal of apoptotic cells can make tors and inflammatory mediators induce apoptosis of
their identification difficult. Historically the detection endothelial cells and vascular SMCs. (Fig. 2).
and quantification of apoptotic cells has relied on
morphological assessment by electron microscopy or
light microscopy.1 Newer techniques rely on the de-
tection of fragmented DNA by terminal transferase Oxidised Low Density Lipoprotein (OxLDL)
mediated dUTP-biotin nick end labelling (TUNEL) or
in situ nick translation (ISEL).7 Both methods have Elevated LDL is a significant risk factor for coronary
artery disease. Specifically, its oxidised form (OxLDL)become the standard technique for the detection of
Eur J Vasc Endovasc Surg Vol 22, November 2001
Apoptosis in Vascular Disease 391
is considered to play a key role in the development
of premature atherosclerosis through the formation of
foam cells and fatty streaks.8 OxLDL is known to be
cytotoxic to cultured endothelial cells and has also
been shown to induce apoptosis, in bovine aortic
endothelial cells and human umbilical vein endothelial
cells (HUVECs).9–11 OxLDL-induced apoptosis is in-
hibited by the addition of the antioxidant vitamins C
and E,12 and is therefore believed to act through the
generation of reactive oxygen species. Cultured vas-
cular smooth muscle cells also undergo apoptosis
Fig. 3. Phase contrast microscopy of cultured human umbilicalwhen exposed to oxLDL and oxysterols.13,14
venous endothelial cells (HUVECs). A: control cells with a char-
acteristic cobblestone morphology, B: After 4 h incubation with
homocysteine and adenosine (0.5 mM) showing contracted apoptotic
cells.
Hyperglycaemia/advanced glycation end products Cytokines and inflammatory mediators
Endothelial cells cultured with high concentrations of The inflammatory cytokines TNF, IL-1 and IFN-glucose (30 mmol/L) for 48 h show increased apoptosis
 have all been identified in human atheroscleroticcompared with those incubated in low concentrations plaques.23 TNF causes endothelial cell apoptosis24of glucose (5 mmol/L).15 High glucose also appears to through the activation of caspase-3 and may be in-induce apoptosis through the generation of hydrogen hibited by specific inhibitors of this enzyme.25 In-peroxide and can be inhibited by antioxidants such terestingly, TNF can also activate a survival pathwayas ascorbic acid.16 Similarly high concentrations of that requires protein synthesis.26 Inhibitors of RNAadvanced glycation end products, the products of non- transcription or protein synthesis can therefore aug-enzymatic glycation of proteins in the circulation, can ment TNF-induced apoptosis of endothelial cells. Ininduce apoptosis of endothelial cells after 48 h.17 In- contrast TNF, does not cause apoptosis of culturedterestingly, the lipid-lowering drug pravastatin can human smooth muscle cells on its own, but does soprevent hyperglycaemia induced apoptosis18 which when combined with IL-1 and IFN-.27 Lipo-contrasts with the proapoptotic effects of the lipophilic polysaccharide also induces human endothelial cellstatins (atorvastatin, simvastatin and lovastatin) on apoptosis in vitro that can be prevented by anti-vascular smooth muscle cells.19 oxidants.12 This effect also occurs in vivo, but unlike
the in vitro setting is dependent on TNF release.28
Angiotensin II, although promoting growth of VSMCs,
induces endothelial apoptosis in vitro in a dose de-
pendent manner.29
Homocysteine
Hyperhomocysteinaemia is, an independent risk factor
for cardiovascular disease, and, is known to cause Reactive oxygen species
endothelial dysfunction.20 We have recently shown
that homocysteine in combination with adenosine, an Elevated reactive oxygen species (ROS) are an early
hallmark of atherogenesis.30 In vitro evidence indicatesimportant substrate in homocysteine metabolism, can
induce apoptosis of cultured HUVECs and human that ROS, the by-product of aerobic metabolism, in-
duce endothelial and smooth muscle cell apoptosis.31long saphenous vein endothelial cells after as little as
4 h incubation21 (Fig. 3). These effects can be prevented ROS may be produced in the vessel wall by macro-
phages within the atherosclerotic plaque or endo-by vitamin B6, B12 and folate,22 cofactors in homo-
cysteine metabolism and currently used as homo- genously by human endothelial and vascular smooth
muscle cells. The proatherosclerotic and proapoptoticcysteine-lowering agents in clinical trials. The latter
finding may represent an important mechanism by factors oxLDL, TNF, glucose and angiotensin II, all
induce endogenous ROS whose effects can be pre-which vitamin supplementation can reduce vascular
injury associated with hyperhomocysteinaemia. vented by antioxidants.30
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Survival Factors Implicated in Preventing Cell-matrix interactions
Vascular Cell Apoptosis
The survival of endothelial cells and vascular smooth
muscle cells is dependent on contact with adjacentShear stress and nitric oxide
cells and the extracellular matrix (Fig. 2). This is me-
diated by cellular adhesion molecules such as theCultured endothelial cells (HUVECs) undergo a basal
level of apoptosis in the absence of flow, which can be integrins, which also function as signalling molecules.
Apoptosis occurs when these contacts are lost.46 Underinhibited by mimicking flow conditions in a perfusion
chamber.32 Laminar flow generates shear stress at the normal circumstances the extracellular matrix gen-
erates survival signals that either suppress apoptoticendothelial cell surface that can prevent apoptosis
induced by different stimuli including TNF, oxLDL pathways or lead to an increase in the activity of
anti-apoptotic pathways such as the Bcl-2 family ofand ROS. This inhibition is mediated by shear stress-
induced release of nitric oxide (NO) that subsequently proteins.47
inactivates caspase-3.33 In the normal vasculature the
shear stress associated with laminar flow causes a
continuous production of NO by endothelial cells,
Apoptosis and Vascular Diseaseproviding protection from injury and apoptosis. How-
ever atherosclerotic plaque-prone areas are typically
Plaquessites of turbulent blood flow and low shear stress, and
are associated with increased cell turnover,34 which is
Early studies in cholesterol-fed swine have shownmost probably secondary to increased apoptosis.35
cell death to be a major component of atherosclerotic
plaque development.48 In situ techniques (TUNEL)
have since confirmed the presence of apoptotic smooth
muscle cells, T-lymphocytes, and macrophages in
Growth factors human atherosclerotic plaques.27,49,50 More recently
Tricot et al.51 have examined carotid endarterectomy
Cultured endothelial cells deprived of growth factor specimens and shown that apoptotic luminal endo-
undergo apoptosis.36 Addition of vascular endothelial thelial cells occur with a greater prevalence in the
growth factor (VEGF) can inhibit apoptosis induced post-stenotic area, a region of low flow and low shear
by TNF,37 ionising radiation38 and disruption of the stress.
extracellular matrix.39 Angiopoietin-1 can also prevent Apoptotic cell death within plaques, as determined
apoptosis in growth factor deprived endothelial cells.40 by the TUNEL technique, ranges from <2% to 30% and
Basic fibroblast growth factor (FGF-2) prevents lipo- is related to the stage of the atherosclerotic plaque.27,49,
popolysaccharide induced endothelial cell apoptosis in 50,52–55 Very little apoptosis occurs in intimal thickening
vivo and serum and growth factor deprivation induced and fatty streaks with the majority of apoptotic cells
apoptosis in vitro.28,36 In cultured human vascular occurring in advanced atherosclerotic plaques within
smooth muscle cells several growth factors (insulin- regions of macrophage infiltration.5
like growth factor, platelet derived growth factor, basic Although the above evidence indicates that apo-
fibroblast growth factor, and transforming growth fac- ptosis does occur within human atherosclerotic
tor) inhibit apoptosis especially under low serum con- plaques, other authors have used electron microscopy
ditions.41–44 to show that despite >10% TUNEL-positive nuclei, the
vast majority of injured and disintegrating cells within
plaques display typical features of cells undergoing
cell death by necrosis.56–58
Although the relative importance of cell death byAtheroprotective factors
apoptosis versus necrosis is unknown we can speculate
that apoptosis may allow plaque stabilisation. Apo-Oestrogen is an established atheroprotective hormone,
which is known to produce beneficial changes in lipid ptotic removal of T-cells and macrophages, which
commonly infiltrate the shoulder region of the fibrousprofile and the regulation of vascular tone. Oestradiol
also maintains endothelial integrity by inhibiting endo- cap, would reduce matrix metalloproteinase (MMP)
synthesis and extracellular matrix breakdown withoutthelial apoptosis induced byTNF.45 Antioxidant vit-
amins C and E, especially in combination, prevent an accompanying inflammatory reaction. Conversely
death of vascular smooth muscle cells in plaques,apoptosis induced by oxLDL, TNF, and glucose.30
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either through apoptosis or necrosis, may lead to a Transplant arteriopathy
weakening of the fibrous cap as a consequence of
reduced collagen and extracellular matrix synthesis Medial SMC loss prior to the development of occlusive
and intimal proliferative lesions is characteristicallyfollowing the loss of smooth muscle cells.
Apoptosis of luminal endothelial cells51 in athero- found in transplant arteriopathy. Experimental evi-
dence using rat arterial allografts suggest that thissclerotic plaques may initiate plaque erosion with
the subsequent promotion of platelet aggregation and SMC loss is due to apoptosis.68 Endothelial damage,
also seen in transplant arteriopathy, appears to be duethrombosis. Apoptotic vascular cells themselves may
also lead to increased plaque thrombogenicity. Both to a Fas-based apoptotic pathway.69
apoptotic smooth muscle cells and endothelial cells
expose phosphatidylserine residues on their surface
in early apoptosis, which in the presence of factor V
Therapeutic Potentialand VII, can act as a substrate for the generation
of thrombin.59 Additionally apoptotic monocytic cells
Apoptotic cells are quickly eliminated by neighbouringhave enhanced tissue factor activity.60 Mallat et al.61
phagocytic cells making in vivo identification difficult.have also identified increased tissue factor expression
Our current understanding of apoptosis in vasculararound apoptotic cells within the central necrotic core
disease therefore depends almost entirely upon in vitroof plaques, indicating that tissue factor is shed from
and in situ data. However, recent techniques, whichapoptotic cells via apoptotic microparticles.
capture shed microparticles released by apoptotic cells,




Apoptosis of smooth muscle cells will occur following
Atherosclerotic plaques in cholesterol-fed rabbits re-balloon injury in animal models. An initial apoptotic
gress when neointimal cell apoptosis is induced byresponse after 30 min62 is followed by persistent apo-
inhibiting the antiapoptotic protein Bcl-x.71 Plaque re-ptosis after two weeks, the latter associated with the
gression also occurs following administration of L-regulation of intimal thickening.63 Studies of human
arginine to induce macrophage apoptosis via NO re-restenotic plaques indicate there may be an increased
lease.72 Interestingly, Schaub et al.73 found that whenapoptotic rate, but there is no consensus. Isner et al.52
vascular smooth muscle cell apoptosis is induced,found an increased apoptotic rate in human restenotic
through the overexpression of death domain proteins,plaques, whereas Bauriedel et al.64 noted reduced levels
macrophages are recruited and neointimal progressionof apoptotic cells in restenotic plaques compared with
rather than regression occurs.primary plaques.
Various attempts to induce apoptosis have been
tried in animal models of neointima formation and
restenosis following angioplasty. Transfection of sui-
cide genes into smooth muscle cells or direct delivery
of pro-apoptotic ligands (Fas-ligand) into the vessel
Aneurysms wall induce smooth muscle cell apoptosis and a sig-
nificant reduction in neointima formation in rabbit
Reduced smooth muscle cell density within the elastic arteries following angioplasty.74 Adopting this ap-
media of human aneurysmal wall is associated with proach in the human clinical setting may however,
increased smooth muscle cell apoptosis.65–67 Further risk the development of aneurysms.
evidence has shown that infiltrating T cells express
cytotoxic mediators such as cytokines, perforin and
Fas/Fas ligand, which are capable of inducing apo-
ptosis. It is hypothesised that these might contribute Inhibition of apoptosis
to the elimination of smooth muscle cells, a source of
collagen and elastin, thereby impairing repair and Currently there is no information on the effect of
inhibiting apoptosis on the progression or com-maintenance of the arterial extracellular matrix tending
to favour aneurysmal wall expansion. plications of vascular disease. In vitro and in situ data
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